Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade

A. de Blasi, M. Lipartiti, F. Pirone, C. Rochat, J. F. Prost, S. Garattini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Tertatolol is a potent new β-blocker with no intrinsic sympathomimetic activity or β12-receptor subtype selectivity. When given at therapeutic doses (5 mg/day) to human subjects it induced a reduction in the β-adrenergic receptor number measured by 3H-CGP 12177 specific binding, without any change in the affinity on intact lymphocytes. This reduction was seen 7 hours (54%), 24 hours (35%), and 48 hours (30%) after a single drug dose. A similar receptor reduction was observed 7 hours (42%), 24 hours (37%), and 48 hours (15%) after 14 doses of the drug. In parallel, the pharmacologic efficacy of the drug was evident from the reduction in supine and upright heart rates and after submaximal exercise; heart rate was reduced to the same extent after single or repeated drug doses. The reduction of receptor number correlated well with the reduction in heart rate in the supine (P <0.001) and upright (P <0.01) positions and after exercise (P <0.02). In in vitro competitive binding experiments tertatolol was found to be a competitive inhibitor of β-adrenergic receptors. However, on intact human lymphocytes preincubated with this drug, tertatolol reduced the density of β-adrenergic receptors. We conclude that tertatolol, besides competitively inhibiting β-adrenergic receptors, induced a marked and lasting decrease in the β-adrenergic receptor number. This effect may be important for its β-blocking effects.

Original languageEnglish
Pages (from-to)245-254
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume39
Issue number3
Publication statusPublished - 1986

Fingerprint

tertatolol
Receptors, Adrenergic, beta
Adrenergic Agents
Adrenergic Receptors
Pharmaceutical Preparations
Heart Rate
Lymphocytes
Sympathomimetics
Competitive Binding

ASJC Scopus subject areas

  • Pharmacology

Cite this

Reduction of beta-adrenergic receptors by tertatolol : An additional mechanism for beta-adrenergic blockade. / de Blasi, A.; Lipartiti, M.; Pirone, F.; Rochat, C.; Prost, J. F.; Garattini, S.

In: Clinical Pharmacology and Therapeutics, Vol. 39, No. 3, 1986, p. 245-254.

Research output: Contribution to journalArticle

de Blasi, A. ; Lipartiti, M. ; Pirone, F. ; Rochat, C. ; Prost, J. F. ; Garattini, S. / Reduction of beta-adrenergic receptors by tertatolol : An additional mechanism for beta-adrenergic blockade. In: Clinical Pharmacology and Therapeutics. 1986 ; Vol. 39, No. 3. pp. 245-254.
@article{b280a2cdd37a499681c36ec7cb641764,
title = "Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockade",
abstract = "Tertatolol is a potent new β-blocker with no intrinsic sympathomimetic activity or β1/β2-receptor subtype selectivity. When given at therapeutic doses (5 mg/day) to human subjects it induced a reduction in the β-adrenergic receptor number measured by 3H-CGP 12177 specific binding, without any change in the affinity on intact lymphocytes. This reduction was seen 7 hours (54{\%}), 24 hours (35{\%}), and 48 hours (30{\%}) after a single drug dose. A similar receptor reduction was observed 7 hours (42{\%}), 24 hours (37{\%}), and 48 hours (15{\%}) after 14 doses of the drug. In parallel, the pharmacologic efficacy of the drug was evident from the reduction in supine and upright heart rates and after submaximal exercise; heart rate was reduced to the same extent after single or repeated drug doses. The reduction of receptor number correlated well with the reduction in heart rate in the supine (P <0.001) and upright (P <0.01) positions and after exercise (P <0.02). In in vitro competitive binding experiments tertatolol was found to be a competitive inhibitor of β-adrenergic receptors. However, on intact human lymphocytes preincubated with this drug, tertatolol reduced the density of β-adrenergic receptors. We conclude that tertatolol, besides competitively inhibiting β-adrenergic receptors, induced a marked and lasting decrease in the β-adrenergic receptor number. This effect may be important for its β-blocking effects.",
author = "{de Blasi}, A. and M. Lipartiti and F. Pirone and C. Rochat and Prost, {J. F.} and S. Garattini",
year = "1986",
language = "English",
volume = "39",
pages = "245--254",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Reduction of beta-adrenergic receptors by tertatolol

T2 - An additional mechanism for beta-adrenergic blockade

AU - de Blasi, A.

AU - Lipartiti, M.

AU - Pirone, F.

AU - Rochat, C.

AU - Prost, J. F.

AU - Garattini, S.

PY - 1986

Y1 - 1986

N2 - Tertatolol is a potent new β-blocker with no intrinsic sympathomimetic activity or β1/β2-receptor subtype selectivity. When given at therapeutic doses (5 mg/day) to human subjects it induced a reduction in the β-adrenergic receptor number measured by 3H-CGP 12177 specific binding, without any change in the affinity on intact lymphocytes. This reduction was seen 7 hours (54%), 24 hours (35%), and 48 hours (30%) after a single drug dose. A similar receptor reduction was observed 7 hours (42%), 24 hours (37%), and 48 hours (15%) after 14 doses of the drug. In parallel, the pharmacologic efficacy of the drug was evident from the reduction in supine and upright heart rates and after submaximal exercise; heart rate was reduced to the same extent after single or repeated drug doses. The reduction of receptor number correlated well with the reduction in heart rate in the supine (P <0.001) and upright (P <0.01) positions and after exercise (P <0.02). In in vitro competitive binding experiments tertatolol was found to be a competitive inhibitor of β-adrenergic receptors. However, on intact human lymphocytes preincubated with this drug, tertatolol reduced the density of β-adrenergic receptors. We conclude that tertatolol, besides competitively inhibiting β-adrenergic receptors, induced a marked and lasting decrease in the β-adrenergic receptor number. This effect may be important for its β-blocking effects.

AB - Tertatolol is a potent new β-blocker with no intrinsic sympathomimetic activity or β1/β2-receptor subtype selectivity. When given at therapeutic doses (5 mg/day) to human subjects it induced a reduction in the β-adrenergic receptor number measured by 3H-CGP 12177 specific binding, without any change in the affinity on intact lymphocytes. This reduction was seen 7 hours (54%), 24 hours (35%), and 48 hours (30%) after a single drug dose. A similar receptor reduction was observed 7 hours (42%), 24 hours (37%), and 48 hours (15%) after 14 doses of the drug. In parallel, the pharmacologic efficacy of the drug was evident from the reduction in supine and upright heart rates and after submaximal exercise; heart rate was reduced to the same extent after single or repeated drug doses. The reduction of receptor number correlated well with the reduction in heart rate in the supine (P <0.001) and upright (P <0.01) positions and after exercise (P <0.02). In in vitro competitive binding experiments tertatolol was found to be a competitive inhibitor of β-adrenergic receptors. However, on intact human lymphocytes preincubated with this drug, tertatolol reduced the density of β-adrenergic receptors. We conclude that tertatolol, besides competitively inhibiting β-adrenergic receptors, induced a marked and lasting decrease in the β-adrenergic receptor number. This effect may be important for its β-blocking effects.

UR - http://www.scopus.com/inward/record.url?scp=0022651187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022651187&partnerID=8YFLogxK

M3 - Article

C2 - 2868822

AN - SCOPUS:0022651187

VL - 39

SP - 245

EP - 254

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -